金吾财讯 | 诺和诺德(NVO)盘前涨超4%，截至发稿，报94.39美元。
消息面上，华泰证券认为，GLP-1已展现较大的市场潜力，而目前海外MNC仅诺和诺德和礼来两巨头销售领先，但尚未形成完整产品矩阵，其他MNC产品仍处于临床阶段，竞争格局尚未定型，产品空缺较大。诺和诺德日前表示，继续按三班倒运作多家工厂，从而满足Wegovy和Ozempic需求。
此外，据市场消息，药物配剂商就诺和诺德糖尿病、减肥药物从短缺名单中移除一事起诉美国药品监管机构。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.